Active Filter(s):
Details:
Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Lead Product(s): Raltegravir Potassium
Therapeutic Area: Infections and Infectious Diseases Product Name: Raltegravir-Generic
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Midas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020